Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
Kelly Van LanckerAn VandeboschStijn VansteelandtPublished in: Pharmaceutical statistics (2020)
Conditional power calculations are frequently used to guide the decision whether or not to stop a trial for futility or to modify planned sample size. These ignore the information in short-term endpoints and baseline covariates, and thereby do not make fully efficient use of the information in the data. We therefore propose an interim decision procedure based on the conditional power approach which exploits the information contained in baseline covariates and short-term endpoints. We will realize this by considering the estimation of the treatment effect at the interim analysis as a missing data problem. This problem is addressed by employing specific prediction models for the long-term endpoint which enable the incorporation of baseline covariates and multiple short-term endpoints. We show that the proposed procedure leads to an efficiency gain and a reduced sample size, without compromising the Type I error rate of the procedure, even when the adopted prediction models are misspecified. In particular, implementing our proposal in the conditional power approach enables earlier decisions relative to standard approaches, whilst controlling the probability of an incorrect decision. This time gain results in a lower expected number of recruited patients in case of stopping for futility, such that fewer patients receive the futile regimen. We explain how these methods can be used in adaptive designs with unblinded sample size re-assessment based on the inverse normal P-value combination method to control Type I error. We support the proposal by Monte Carlo simulations based on data from a real clinical trial.
Keyphrases
- clinical trial
- end stage renal disease
- monte carlo
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- study protocol
- molecular dynamics
- decision making
- healthcare
- machine learning
- patient reported outcomes
- open label
- quality improvement
- social media
- smoking cessation
- combination therapy